
389: Hims' Super Bowl fallout, and the FDA reverses course
The Readout Loud
00:00
Compass Pathways announces positive phase 3 results
Hosts introduce Compass Pathways' depression drug success and note primary endpoint details and market reaction.
Play episode from 05:58
Transcript


